Synthetic investigational new drugs for the treatment of tuberculosis

Expert Opinion on Investigational Drugs

Volumn 25, Issue 2, 2016, Pages 183-193

  Kwon, Yong Soo ^a   Koh, Won Jung ^b  

^a Chonnam National University Medical School   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Antitubercular agents; bedaquiline; delamanid; multidrug resistant tuberculosis; tuberculosis

Indexed keywords

1,2 ETHYLENEDIAMINE; BEDAQUILINE; DELAMANID; ETHAMBUTOL; IMIDAZOPYRIDINE DERIVATIVE; ISONIAZID PLUS RIFAMPICIN; LINEZOLID; MOXIFLOXACIN; N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; NEW DRUG; POSIZOLID; PRETOMANID; RIFAMPICIN; RIFAMYCIN; RIFAPENTINE; SUTEZOLID; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

DRUG SAFETY; DRUG TOLERABILITY; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); QT PROLONGATION; REVIEW; TREATMENT DURATION; ANIMAL; DRUG DESIGN; DRUG EFFECTS; ISOLATION AND PURIFICATION; MICROBIOLOGY; MULTIDRUG RESISTANCE; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANIMALS; ANTITUBERCULAR AGENTS; DRUG DESIGN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUGS, INVESTIGATIONAL; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84957437761     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2016.1121993     Document Type: Review

References (100)

1. World Health Organization. Global tuberculosis report 2015. WHO/HTM/TB/2015.22. Geneva: World Health Organization; 2015 [cited 2015 Oct 30]. Available at: http://www.who.int/tb/publications/global-report/en/.
2. Keshavjee S, Gelmanova IY, Farmer PE., et al. Treatment of extensively drug-resistant tuberculosis in Tomsk, Russia: a retrospective cohort study. Lancet. 2008; 372: 1403-1409.
3. Kim DH, Kim HJ, Park SK., et al. Treatment outcomes and long-term survival in patients with extensively drug-resistant tuberculosis. Am J Respir Crit Care Med. 2008; 178: 1075-1082.
4. Kwon YS, Kim YH, Suh GY., et al. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis. Clin Infect Dis. 2008; 47: 496-502.
5. Mitnick CD, Shin SS, Seung KJ., et al. Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med. 2008; 359: 563-574.
6. Dheda K, Shean K, Zumla A., et al. Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet. 2010; 375: 1798-1807.
7. Jacobson KR, Tierney DB, Jeon CY., et al. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis. 2010; 51: 6-14.
8. Orenstein EW, Basu S, Shah NS., et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis. 2009; 9: 153-161.
9. Johnston JC, Shahidi NC, Sadatsafavi M., et al. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS One. 2009; 4: e6914.
10. Kim DH, Kim HJ, Park SK., et al. Treatment outcomes and survival based on drug resistance patterns in multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2010; 182: 113-119.
11. Mitnick CD, Franke MF, Rich ML., et al. Aggressive regimens for multidrug-resistant tuberculosis decrease all-cause mortality. PLoS One. 2013; 8: e58664.
12. Pietersen E, Ignatius E, Streicher EM., et al. Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort study. Lancet. 2014; 383: 1230-1239.
13. Loveday M, Wallengren K, Brust J., et al. Community-based care vs. centralised hospitalisation for MDR-TB patients, KwaZulu-Natal, South Africa. Int J Tuberc Lung Dis. 2015; 19: 163-171.
14. Garrido Mda S, Buhrer-Sekula S, Souza AB., et al. Multidrug-resistant tuberculosis in the Amazonas State, Brazil, 2000-2011. Int J Tuberc Lung Dis. 2015; 19: 531-536.
15. Kwak N, Kim HR, Yoo CG., et al. Changes in treatment outcomes of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2015; 19: 525-530.
16. Ahuja SD, Ashkin D, Avendano M., et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med. 2012; 9: e1001300.
17. Falzon D, Gandhi N, Migliori GB., et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J. 2013; 42: 156-168.
18. Migliori GB, Sotgiu G, Gandhi NR., et al. Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis. Eur Respir J. 2013; 42: 169-179.
19. Zumla A, Nahid P, Cole ST. Advances in the development of new tuberculosis drugs and treatment regimens. Nat Rev Drug Discov. 2013; 12: 388-404.
20. Kwon YS, Jeong BH, Koh WJ. Tuberculosis: clinical trials and new drug regimens. Curr Opin Pulm Med. 2014; 20: 280-286.
21. Olaru ID, von Groote-Bidlingmaier F, Heyckendorf J., et al. Novel drugs against tuberculosis: a clinicians perspective. Eur Respir J. 2015; 45: 1119-1131.
22. Global alliance for TB drug development. [Internet]. 2015. [cited 2015 Oct 27]. Available from: http://www.tballiance.org/downloads/Pipeline/TBA-Pipeline-Q3-2015.pdf.
23. Global TB drug pipeline. Working Group On New TB Drugs. September 2015. [Internet]. 2015. [cited 2015 Oct 27]. Available from: http://www.newtbdrugs.org/pipeline.php.
24. Kakkar AK, Dahiya N. Bedaquiline for the treatment of resistant tuberculosis: promises and pitfalls. Tuberculosis (Edinb). 2014; 94: 357-362.
25. Andries K, Verhasselt P, Guillemont J., et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science. 2005; 307: 223-227.
26. Rustomjee R, Diacon AH, Allen J., et al. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrob Agents Chemother. 2008; 52: 2831-2835.
27. Diacon AH, Pym A, Grobusch M., et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med. 2009; 360: 2397-2405.
28. Diacon AH, Donald PR, Pym A., et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother. 2012; 56: 3271-3276.
29. Diacon AH, Pym A, Grobusch MP., et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med. 2014; 371: 723-732.
30. Mase S, Chorba T, Lobue PKC. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis. MMWR Recomm Rep. 2013; 62: 1-12.
31. World Health Organization. Interim guidance on the use of bedaquiline to treat MDR-TB. WHO/HTM/TB/2013.6. Geneva: World Health Organization; 2013 [cited 2015 Aug 14]. Available at http://www.who.int/tb/challenges/mdr/bedaquiline/en/.
32. Svensson EM, Dooley KE, Karlsson MO. Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection. Antimicrob Agents Chemother. 2014; 58: 6406-6412.
33. Diacon AH, Dawson R, von Groote-Bidlingmaier F., et al. Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline. Am J Respir Crit Care Med. 2015; 191: 943-953.
34. Hartkoorn RC, Uplekar S, Cole ST. Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2014; 58: 2979-2981.
35. Andries K, Villellas C, Coeck N., et al. Acquired resistance of Mycobacterium tuberculosis to bedaquiline. PLoS One. 2014; 9: e102135.
36. Salfinger M, Migliori GB. Bedaquiline: 10 years later, the drug susceptibility testing protocol is still pending. Eur Respir J. 2015; 45: 317-321.
37. Mukherjee T, Boshoff H. Nitroimidazoles for the treatment of TB: past, present and future. Future Med Chem. 2011; 3: 1427-1454.
38. Matsumoto M, Hashizume H, Tomishige T., et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med. 2006; 3: e466.
39. Diacon AH, Dawson R, Hanekom M., et al. Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients. Int J Tuberc Lung Dis. 2011; 15: 949-954.
40. Gler MT, Skripconoka V, Sanchez-Garavito E., et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med. 2012; 366: 2151-2160.
41. Skripconoka V, Danilovits M, Pehme L., et al. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J. 2013; 41: 1393-1400.
42. Kwon YS, Jeong BH, Koh WJ. Delamanid when other anti-tuberculosis-treatment regimens failed due to resistance or tolerability. Expert Opin Pharmacother. 2015; 16: 253-261.
43. Stover CK, Warrener P, VanDevanter DR., et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature. 2000; 405: 962-966.
44. Singh R, Manjunatha U, Boshoff HI., et al. PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science. 2008; 322: 1392-1395.
45. Tyagi S, Nuermberger E, Yoshimatsu T., et al. Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis. Antimicrob Agents Chemother. 2005; 49: 2289-2293.
46. Nuermberger E, Tyagi S, Tasneen R., et al. Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis. Antimicrob Agents Chemother. 2008; 52: 1522-1524.
47. Dutta NK, Alsultan A, Gniadek TJ., et al. Potent rifamycin-sparing regimen cures guinea pig tuberculosis as rapidly as the standard regimen. Antimicrob Agents Chemother. 2013; 57: 3910-3916.
48. Diacon AH, Dawson R, von Groote-Bidlingmaier F., et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet. 2012; 380: 986-993.
49. Dawson R, Diacon AH, Everitt D., et al. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis. Lancet. 2015; 385: 1738-1747.
50. Dooley KE, Luetkemeyer AF, Park JG., et al. Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 with concomitant lopinavir-ritonavir, efavirenz, or rifampin. Antimicrob Agents Chemother. 2014; 58: 5245-5252.
51. Kmentova I, Sutherland HS, Palmer BD., et al. Synthesis and structure-activity relationships of aza-and diazabiphenyl analogues of the antitubercular drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1, 3]oxazine (PA-824). J Med Chem. 2010; 53: 8421-8439.
52. Upton AM, Cho S, Yang TJ., et al. In vitro and in vivo activities of the nitroimidazole TBA-354 against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2015; 59: 136-144.
53. Gumbo T, Louie A, Deziel MR., et al. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob Agents Chemother. 2007; 51: 3781-3788.
54. Rosenthal IM, Tasneen R, Peloquin CA., et al. Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis. Antimicrob Agents Chemother. 2012; 56: 4331-4340.
55. de Steenwinkel JE, Aarnoutse RE, de Knegt GJ., et al. Optimization of the rifampin dosage to improve the therapeutic efficacy in tuberculosis treatment using a murine model. Am J Respir Crit Care Med. 2013; 187: 1127-1134.
56. Boeree MJ, Diacon AH, Dawson R., et al. A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis. Am J Respir Crit Care Med. 2015; 191: 1058-1065.
57. Munsiff SS, Kambili C, Ahuja SD. Rifapentine for the treatment of pulmonary tuberculosis. Clin Infect Dis. 2006; 43: 1468-1475.
58. Sterling TR, Villarino ME, Borisov AS., et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011; 365: 2155-2166.
59. Vernon A, Burman W, Benator D., et al. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. Lancet. 1999; 353: 1843-1847.
60. Benator D, Bhattacharya M, Bozeman L., et al. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet. 2002; 360: 528-534.
61. Dorman SE, Goldberg S, Stout JE., et al. Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium. J Infect Dis. 2012; 206: 1030-1040.
62. Rosenthal IM, Zhang M, Williams KN., et al. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med. 2007; 4: e344.
63. Mitchison DA. Pharmacokinetic/pharmacodynamic parameters and the choice of high-dosage rifamycins. Int J Tuberc Lung Dis. 2012; 16: 1186-1189.
64. Dorman SE, Savic RM, Goldberg S., et al. Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial. Am J Respir Crit Care Med. 2015; 191: 333-343.
65. Cox H, Ford N. Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis. Int J Tuberc Lung Dis. 2012; 16: 447-454.
66. Sotgiu G, Centis R, DAmbrosio L., et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J. 2012; 40: 1430-1442.
67. Koh WJ, Kang YR, Jeon K., et al. Daily 300 mg dose of linezolid for multidrug-resistant and extensively drug-resistant tuberculosis: updated analysis of 51 patients. J Antimicrob Chemother. 2012; 67: 1503-1507.
68. Jeong BH, Jeon K, Park HY., et al. Outcomes of pulmonary MDR-TB: impacts of fluoroquinolone resistance and linezolid treatment. J Antimicrob Chemother. 2015; 70: 3127-3133.
69. Lee M, Lee J, Carroll MW., et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med. 2012; 367: 1508-1518.
70. Lee M, Cho SN, Barry CE 3rd., et al. Linezolid for XDR-TB-final study outcomes. N Engl J Med. 2015; 373: 290-291.
71. Tang S, Yao L, Hao X., et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China. Eur Respir J. 2015; 45: 161-170.
72. Chang KC, Yew WW, Cheung SW., et al. Can intermittent dosing optimize prolonged linezolid treatment of difficult multidrug-resistant tuberculosis? Antimicrob Agents Chemother. 2013; 57: 3445-3449.
73. Bolhuis MS, van Altena R, van Soolingen D., et al. Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients. Eur Respir J. 2013; 42: 1614-1621.
74. Yip PC, Kam KM, Lam ET., et al. In vitro activities of PNU-100480 and linezolid against drug-susceptible and drug-resistant Mycobacterium tuberculosis isolates. Int J Antimicrob Agents. 2013; 42: 96-97.
75. Williams KN, Stover CK, Zhu T., et al. Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model. Antimicrob Agents Chemother. 2009; 53: 1314-1319.
76. Williams KN, Brickner SJ, Stover CK., et al. Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis. Am J Respir Crit Care Med. 2009; 180: 371-376.
77. Wallis RS, Jakubiec WM, Kumar V., et al. Pharmacokinetics and whole-blood bactericidal activity against Mycobacterium tuberculosis of single doses of PNU-100480 in healthy volunteers. J Infect Dis. 2010; 202: 745-751.
78. Wallis RS, Jakubiec W, Kumar V., et al. Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis. Antimicrob Agents Chemother. 2011; 55: 567-574.
79. Wallis RS, Dawson R, Friedrich SO., et al. Mycobactericidal activity of sutezolid (PNU-100480) in sputum (EBA) and blood (WBA) of patients with pulmonary tuberculosis. PLoS One. 2014; 9: e94462.
80. Balasubramanian V, Solapure S, Iyer H., et al. Bactericidal activity and mechanism of action of AZD5847, a novel oxazolidinone for treatment of tuberculosis. Antimicrob Agents Chemother. 2014; 58: 495-502.
81. Werngren J, Wijkander M, Perskvist N., et al. In vitro activity of AZD5847 against geographically diverse clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2014; 58: 4222-4223.
82. Balasubramanian V, Solapure S, Shandil R., et al. Pharmacokinetic and pharmacodynamic evaluation of AZD5847 in a mouse model of tuberculosis. Antimicrob Agents Chemother. 2014; 58: 4185-4190.
83. Tahlan K, Wilson R, Kastrinsky DB., et al. SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2012; 56: 1797-1809.
84. Sacksteder KA, Protopopova M, Barry CE 3rd., et al. Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action. Future Microbiol. 2012; 7: 823-837.
85. Reddy VM, Einck L, Andries K., et al. In vitro interactions between new antitubercular drug candidates SQ109 and TMC207. Antimicrob Agents Chemother. 2010; 54: 2840-2846.
86. Reddy VM, Dubuisson T, Einck L., et al. SQ109 and PNU-100480 interact to kill Mycobacterium tuberculosis in vitro. J Antimicrob Chemother. 2012; 67: 1163-1166.
87. Heinrich N, Dawson R, du Bois J., et al. Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients. J Antimicrob Chemother. 2015; 70: 1558-1566.
88. Makarov V, Manina G, Mikusova K., et al. Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis. Science. 2009; 324: 801-804.
89. Pasca MR, Degiacomi G, Ribeiro AL., et al. Clinical isolates of Mycobacterium tuberculosis in four European hospitals are uniformly susceptible to benzothiazinones. Antimicrob Agents Chemother. 2010; 54: 1616-1618.
90. Lechartier B, Hartkoorn RC, Cole ST. In vitro combination studies of benzothiazinone lead compound BTZ043 against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2012; 56: 5790-5793.
91. Makarov V, Lechartier B, Zhang M., et al. Towards a new combination therapy for tuberculosis with next generation benzothiazinones. EMBO Mol Med. 2014; 6: 372-383.
92. Lechartier B, Cole ST. Mode of action of clofazimine and combination therapy with benzothiazinones against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2015; 59: 4457-4463.
93. Pethe K, Bifani P, Jang J., et al. Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. Nat Med. 2013; 19: 1157-1160.
94. Kang S, Kim RY, Seo MJ., et al. Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi-and extensively-drug-resistant anti-tuberculosis agent. J Med Chem. 2014; 57: 5293-5305.
95. McIlleron H, Abdel-Rahman S, Dave JA., et al. Special populations and pharmacogenetic issues in tuberculosis drug development and clinical research. J Infect Dis. 2015; 211 (Suppl 3): S115-25.
96. Nachman S, Ahmed A, Amanullah F., et al. Towards early inclusion of children in tuberculosis drugs trials: a consensus statement. Lancet Infect Dis. 2015; 15: 711-720.
97. Odone A, Houben RM, White RG., et al. The effect of diabetes and undernutrition trends on reaching 2035 global tuberculosis targets. Lancet Diabetes Endocrinol. 2014; 2: 754-764.
98. Mitnick C, Bayona J, Palacios E., et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med. 2003; 348: 119-128.
99. Putri FA, Burhan E, Nawas A., et al. Body mass index predictive of sputum culture conversion among MDR-TB patients in Indonesia. Int J Tuberc Lung Dis. 2014; 18: 564-570.
100. Jeremiah K, Denti P, Chigutsa E., et al. Nutritional supplementation increases rifampin exposure among tuberculosis patients coinfected with HIV. Antimicrob Agents Chemother. 2014; 58: 3468-3474.